TetraLogic Announces Termination of Public Offering
06 mai 2015 12h52 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial
06 mai 2015 10h14 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Pricing of $25 Million Public Offering
01 mai 2015 08h56 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 1, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Public Offering of Common Stock
30 avr. 2015 16h01 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
21 avr. 2015 08h00 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
20 avr. 2015 08h00 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa. and KENILWORTH, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and...
TetraLogic to Present at the 14th Annual Needham Healthcare Conference
09 avr. 2015 10h11 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...
TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update
26 févr. 2015 16h10 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Feb. 26, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
18 déc. 2014 07h00 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Dec. 18, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with...
TetraLogic Provides Update on Ovarian Cancer Study
16 déc. 2014 07h00 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Dec. 16, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with...